Shylet Chengedza, Ph.D. - Publications
Affiliations: | 2009 | University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States |
Area:
Biochemistry, Oncology, Cell BiologyYear | Citation | Score | |||
---|---|---|---|---|---|
2010 | Chengedza S, Benbrook DM. NF-kappaB is involved in SHetA2 circumvention of TNF-alpha resistance, but not induction of intrinsic apoptosis. Anti-Cancer Drugs. 21: 297-305. PMID 20032777 DOI: 10.1097/Cad.0B013E3283350E43 | 0.58 | |||
2010 | Moxley KM, Chengedza S, Benbrook DM. Erratum to “Induction of death receptor ligand-mediated apoptosis in epithelial ovarian carcinoma: The search for sensitizing agents” [Gynecol. Oncol. 115 (2009) 438–442] Gynecologic Oncology. 117: 510. DOI: 10.1016/J.Ygyno.2010.02.026 | 0.542 | |||
2009 | Moxley KM, Chengedza S, Benbrook DM. Induction of death receptor ligand-mediated apoptosis in epithelial ovarian carcinoma: The search for sensitizing agents. Gynecologic Oncology. 115: 438-42. PMID 19804900 DOI: 10.1016/J.Ygyno.2009.09.007 | 0.629 | |||
2009 | Liu T, Masamha CP, Chengedza S, Berlin KD, Lightfoot S, He F, Benbrook DM. Development of flexible-heteroarotinoids for kidney cancer. Molecular Cancer Therapeutics. 8: 1227-38. PMID 19417155 DOI: 10.1158/1535-7163.Mct-08-1069 | 0.511 | |||
2009 | Myers T, Chengedza S, Lightfoot S, Pan Y, Dedmond D, Cole L, Tang Y, Benbrook DM. Flexible heteroarotinoid (Flex-Het) SHetA2 inhibits angiogenesis in vitro and in vivo. Investigational New Drugs. 27: 304-18. PMID 18802666 DOI: 10.1007/S10637-008-9175-7 | 0.635 | |||
2008 | Benbrook DM, Lightfoot S, Ranger-Moore J, Liu T, Chengedza S, Berry WL, Dozmorov I. Gene expression analysis of biological systems driving an organotypic model of endometrial carcinogenesis and chemoprevention. Gene Regulation and Systems Biology. 2: 21-42. PMID 19784388 DOI: 10.4137/Grsb.S344 | 0.549 | |||
Show low-probability matches. |